Novel Therapy Shows Promising Results In On-Going Trials, Receives 3 Orphan Drug Designations From The FDA

Vlad Vitoc, MD, MBA; CEO & Chairman of MAIA Biotechnology (NYSE: MAIA), was a guest on Benzinga’s All Access.

MAIA is a targeted therapy immuno-oncology company focused on developing and commercializing drugs targeting cancers with novel mechanisms of action.

The company’s lead program is THIO. The novel therapy “opens” the telomere cap of cancerous DNA, leading to rapid cell death. 

Watch the full interview here:

Featured photo by Braňo on Unsplash.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.